|
S
Sunday
|
M
Monday
|
T
Tuesday
|
W
Wednesday
|
T
Thursday
|
F
Friday
|
S
Saturday
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
|
0 events,
|
1 event,
Life Sciences Masters™ 2026
Save the date for the Fifth Annual Life Sciences Masters™ 2026 program, a part of the IPWatchdog Masters™ series. The program is scheduled for Monday, November 9, through Tuesday, November 10, 2026, at IPWatchdog Studios in Ashburn, VA. Details to follow... |
1 event, |
0 events,
|
1 event,
-
As access to inter partes review (IPR) becomes less predictable, accused infringers and other potential challengers are taking a fresh look at ex parte reexamination, which has become known as EPR. Although reexamination can provide an important alternative for challenging patentability, proceedings before the Central Reexamination Unit (CRU) present different procedural constraints, strategic tradeoffs, and potential traps for the unwary…
Free
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
1 event,
-
A commercial biologic may be protected by patents covering formulations, dosing regimens, methods of treatment, manufacturing and purification processes, delivery systems, and other product attributes. That means for biologics, expiration of the foundational composition-of-matter patent rarely determines when patent protection effectively ends or biosimilar competition can begin. This makes a comprehensive patent landscape. Today, AI is changing the scale…
Free
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
Our website uses cookies to provide you with a better experience. Read our privacy policy for more information.Accept and Close